Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a single-institution, single arm trial of Toripalimab with neoadjuvant carboplatin
and paclitaxel for locally advanced esophageal squamous cell carcinoma (ESCC).The primary
study hypothesis is that the patients who received Toripalimab combined with carboplatin and
paclitaxel will increase complete pathologic response rate.